Vivaldi Capital Management LLC bought a new position in Amgen, Inc. (NASDAQ:AMGN) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 1,306 shares of the medical research company’s stock, valued at approximately $254,000.

Several other institutional investors and hedge funds have also recently modified their holdings of AMGN. Ruggie Capital Group increased its holdings in Amgen by 297.1% in the 4th quarter. Ruggie Capital Group now owns 135 shares of the medical research company’s stock valued at $26,000 after purchasing an additional 101 shares in the last quarter. Arlington Partners LLC increased its holdings in Amgen by 86.7% in the 4th quarter. Arlington Partners LLC now owns 140 shares of the medical research company’s stock valued at $27,000 after purchasing an additional 65 shares in the last quarter. Massey Quick Simon & CO. LLC increased its holdings in Amgen by 710.5% in the 4th quarter. Massey Quick Simon & CO. LLC now owns 154 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 135 shares in the last quarter. Next Capital Management LLC acquired a new stake in Amgen in the 4th quarter valued at $33,000. Finally, Essex Investment Management Co. LLC acquired a new stake in Amgen in the 4th quarter valued at $39,000. 79.18% of the stock is currently owned by institutional investors and hedge funds.

Shares of Amgen stock opened at $193.89 on Thursday. The company has a debt-to-equity ratio of 2.36, a current ratio of 2.79 and a quick ratio of 2.57. The stock has a market cap of $118.87 billion, a PE ratio of 13.46, a price-to-earnings-growth ratio of 2.36 and a beta of 1.21. Amgen, Inc. has a 1-year low of $165.22 and a 1-year high of $210.19.

Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, January 29th. The medical research company reported $3.42 earnings per share for the quarter, beating the consensus estimate of $3.26 by $0.16. The company had revenue of $6.23 billion during the quarter, compared to the consensus estimate of $5.88 billion. Amgen had a return on equity of 66.74% and a net margin of 35.35%. During the same period last year, the firm earned $2.89 earnings per share. On average, analysts predict that Amgen, Inc. will post 13.97 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Friday, June 7th. Stockholders of record on Friday, May 17th will be given a dividend of $1.45 per share. The ex-dividend date of this dividend is Thursday, May 16th. This represents a $5.80 annualized dividend and a dividend yield of 2.99%. Amgen’s payout ratio is 40.28%.

In other news, Director Ronald D. Sugar sold 2,000 shares of the stock in a transaction dated Thursday, February 7th. The shares were sold at an average price of $190.00, for a total transaction of $380,000.00. Following the transaction, the director now owns 14,988 shares of the company’s stock, valued at $2,847,720. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold 6,000 shares of company stock worth $1,144,120 in the last ninety days. Corporate insiders own 0.27% of the company’s stock.

Several brokerages recently issued reports on AMGN. Oppenheimer set a $224.00 price target on Amgen and gave the company a “buy” rating in a report on Sunday, January 27th. Morgan Stanley lowered their price target on Amgen from $213.00 to $212.00 and set an “overweight” rating for the company in a report on Wednesday, December 19th. Mizuho reiterated a “buy” rating and issued a $211.00 price target on shares of Amgen in a report on Tuesday, February 26th. BidaskClub downgraded Amgen from a “buy” rating to a “hold” rating in a report on Wednesday, February 20th. Finally, Citigroup raised their target price on Amgen from $204.00 to $210.00 and gave the company a “neutral” rating in a research note on Friday, January 4th. Eleven analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $209.00.

TRADEMARK VIOLATION WARNING: This report was originally published by Watch List News and is owned by of Watch List News. If you are reading this report on another site, it was illegally stolen and republished in violation of United States and international copyright laws. The original version of this report can be read at https://www.watchlistnews.com/vivaldi-capital-management-llc-buys-shares-of-1306-amgen-inc-amgn/2954594.html.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.

Featured Article: Call Option Volume

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.